Peptides for Post-COVID Lung Damage: Repairing and Restoring Lung Function

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies are emerging as crucial interventions for post-COVID lung damage, targeting persistent inflammation, fibrosis, and vascular dysfunction. Aviptadil, SPIKENET, and BPC-157 show promise in promoting lung repair, reducing inflammation, and restoring respiratory function, offering a more direct approach to recovery than supportive care alone.

Peptides: A Targeted Approach to Post-COVID Lung Damage

The aftermath of COVID-19 often leaves patients with persistent lung damage, including fibrosis, inflammation, and impaired respiratory function. While supportive care is essential, emerging peptide therapies are offering targeted interventions to repair and restore lung health in the post-COVID landscape.

Aviptadil: Combating Acute and Persistent Lung Injury

Aviptadil, a synthetic form of Vasoactive Intestinal Peptide (VIP), has demonstrated significant potential in treating severe COVID-19-related respiratory failure. Clinical studies have shown that Aviptadil can lead to rapid clinical recovery from critical COVID-19 pneumonia, particularly in patients with comorbidities (ScienceDirect, 2021). Its potent anti-inflammatory and vasodilatory properties help reduce pulmonary edema, improve oxygenation, and protect lung cells from further damage. Research also suggests that inhaled Aviptadil offers hope for the recovery of lung damage due to COVID-19 (PMC, 2025), making it a key peptide in addressing both acute and persistent lung issues.

SPIKENET: Impeding Disease Progression in Long COVID

For the complex challenges of Long COVID, the innovative peptide SPIKENET is emerging as a promising therapeutic agent. Proposed by researchers (PMC, 2024), SPIKENET aims to effectively impede disease progression by targeting the underlying mechanisms of persistent inflammation and cellular dysfunction seen in Long COVID. This peptide represents a novel strategy to address the chronic symptoms and ongoing lung damage experienced by many post-COVID patients.

BPC-157: Enhancing Recovery and Cytoprotection

BPC-157, a stable gastric pentadecapeptide, is gaining recognition for its cytoprotective and regenerative properties, which are highly relevant for post-COVID lung damage. Some research studies indicate that BPC-157 can enhance the clinical management of Long COVID due to its anti-inflammatory and cytoprotective effects (LIVV Natural). This peptide supports tissue healing and reduces inflammation, crucial for repairing damaged lung tissue and restoring its function after viral insult. Its ability to promote regeneration makes it a valuable tool in the recovery process.

TIP Peptide: Reducing Vascular Complications

The TIP peptide has shown promise in reducing vascular problems associated with COVID-19-induced ARDS. Research from Augusta University (2023) demonstrated that TIP peptide treatment could reduce oxidative stress, even after spike protein delivery. This is particularly important as COVID-19 can cause significant endothelial damage and microvascular dysfunction in the lungs. By mitigating oxidative stress, TIP peptide helps preserve the integrity of the pulmonary vasculature, which is vital for long-term lung health.

Peptide Therapies vs. Symptomatic Management

Post-COVID lung damage often necessitates a multifaceted approach, with conventional treatments focusing on symptomatic management, such as respiratory rehabilitation and corticosteroids for inflammation. While these are important, they often do not directly address the cellular and molecular damage. Peptide therapies, in contrast, offer a more direct and regenerative approach. For example, Aviptadil directly improves oxygenation and reduces inflammation, while SPIKENET targets the chronic inflammatory pathways of Long COVID. BPC-157 actively promotes tissue repair and cytoprotection, mechanisms that go beyond mere symptom relief. This distinction highlights the potential for peptides to not only alleviate symptoms but also to actively heal and restore lung function, offering a more comprehensive recovery strategy compared to treatments that primarily manage symptoms.

Clinical Takeaway

The landscape of post-COVID lung damage treatment is evolving rapidly, with peptide therapies emerging as powerful tools for repair and restoration. By leveraging the anti-inflammatory, regenerative, and protective properties of peptides like Aviptadil, SPIKENET, BPC-157, and TIP, clinicians can offer more targeted and effective interventions. These peptides hold the potential to mitigate persistent inflammation, reduce fibrosis, and improve overall lung function, ultimately enhancing the recovery and long-term health of individuals affected by post-COVID lung damage. Further clinical research will solidify their role in standard treatment protocols.